Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Rhea-AI Summary

Allergan Aesthetics (NYSE: ABBV) announced its fourth annual CoolMonth promotion running April 1–30, 2026, offering $400 off first-time CoolSculpting treatments for eligible Allē members and social giveaways up to $5,000.

CoolSculpting and CoolSculpting Elite are FDA-cleared for specific visible fat bulges and submental laxity; they are not weight-loss treatments. Entry and eligibility details apply.

News Market Reaction – ABBV

+2.05%

+2.05% Session close to close

In the Mar 31 session, ABBV gained 2.05%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Allergan Aesthetics’ strategy to deepen consumer engagement with CoolSc...

Analysis

This announcement highlights Allergan Aesthetics’ strategy to deepen consumer engagement with CoolSculpting® through CoolMonth 2026, including a $400 first-treatment discount and giveaways of up to $5,000. It reinforces CoolSculpting’s positioning as an FDA-cleared, nonsurgical fat-reduction option across multiple body areas. In context of recent aesthetics data at AAD and AMWC, investors may watch how such promotions translate into procedure volumes and how they complement AbbVie’s broader dermatology and aesthetics portfolio developments.

Key Figures

First-time discount: $400 off Giveaway value: Up to $5,000 Consumers considering contouring: 50% +5 more

8 metrics

First-time discount $400 off Promotion for first CoolSculpting body contouring treatment during CoolMonth 2026

Giveaway value Up to $5,000 Potential CoolSculpting value in CoolMonth Instagram giveaways

Consumers considering contouring 50% Reported share of people who have considered body contouring treatments

Survey sample size 200 consumers Online survey in 2023 of body-contouring–interested consumers

Survey age range 25–55 years Age range of surveyed consumers in 2023 body contouring survey

Income threshold >$75,000 Household income requirement for surveyed consumers

Offer window start April 1, 2026 Start date for $400 CoolMonth first-time promotion

Offer window end April 30, 2026 End date for $400 CoolMonth first-time promotion

Historical Context

5 past events · Latest: Mar 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 30	Aesthetics data update	Positive	+1.8%	Phase 3 and real-world TrenibotE aesthetics findings presented at AAD.
Mar 27	Dermatology evidence	Positive	-0.8%	24 abstracts on immune-mediated skin diseases at AAD with long-term data.
Mar 26	AMWC aesthetics posters	Positive	+1.9%	21 e-posters on neurotoxin, fillers, and CoolSculpting evidence at AMWC.
Mar 26	HA injectables positioning	Positive	+1.9%	JUVÉDERM branding around "Undetectable Era" and global consumer research.
Mar 24	MLB partnership	Positive	+0.1%	Multi-year MLB deal expanding Striking Out Cancer with per-strikeout donations.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent AbbVie/Allergan Aesthetics news has usually seen positive price reactions, though there was one notable divergence where strong dermatology data coincided with a modest decline.

Recent Company History

Over the past week, AbbVie and Allergan Aesthetics have focused on aesthetics and dermatology leadership, with multiple data-heavy presentations at AAD and AMWC and a high-visibility MLB partnership. These events often coincided with modestly positive moves, such as gains of 1.9% on March 26, 2026 and 1.78% on March 30, 2026. Today’s CoolMonth promotion news continues the theme of leveraging Allergan’s aesthetics portfolio and prior CoolSculpting evidence to drive consumer engagement rather than introducing new clinical data.

Key Terms

nonsurgical fat reduction, body contouring treatments, fda-cleared, glp-1 medication, +3 more

7 terms

nonsurgical fat reduction medical

"CoolSculpting®, the treatment doctors use most for nonsurgical fat reduction."

Non­surgical fat reduction covers medical and aesthetic procedures that reduce pockets of body fat without cutting the skin or requiring general anesthesia, using tools such as controlled cooling, heat, ultrasound or injections. Investors watch this category because it represents a growing consumer market with lower procedure risk, faster recovery and often repeat business, similar to choosing a quick service over a full renovation. Market size, device approvals, clinic adoption and patient demand directly affect revenue potential and regulatory or technology risk.

body contouring treatments medical

"50% of people reportedly have considered body contouring treatments (invasive and noninvasive)"

Body contouring treatments are medical and cosmetic procedures that reshape or firm specific areas of the body—using surgery, lasers, injections, cooling, or other devices—to remove fat, tighten skin, or improve body proportions. Think of them as sculpting or tailoring for a person’s silhouette. Investors track this sector because demand, pricing, regulatory approvals, technology shifts, and consumer spending directly affect company revenues and profit margins in medical-device, clinic, and beauty markets.

fda-cleared regulatory

"It is an FDA-cleared product proven to contour the body"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

glp-1 medication medical

"body changes following weight loss with GLP-1 medication, noticing specific areas"

A GLP-1 medication is a type of drug that mimics a natural gut hormone (glucagon-like peptide-1) to lower blood sugar and often reduce appetite and body weight; think of it as a thermostat that helps the body regulate glucose and hunger. It matters to investors because strong demand, pricing, regulatory approvals, patent status and manufacturing capacity for these medicines can drive sales growth, corporate valuations and sector-wide competition.

submental medical

"fat bulges in the submental (under the chin) and submandibular (under the jawline)"

The submental area is the region directly beneath the chin, encompassing the soft tissue and neckline where fat or sagging skin can create a double chin. For investors, it matters because medical devices, cosmetic injectables, surgical procedures, and skincare products targeting this small, visible zone can drive sales, regulatory filings, and marketing campaigns; think of it as a focused product market similar to treatments for the eye or lip area.

submandibular medical

"the submental (under the chin) and submandibular (under the jawline) areas"

The word describes the area located beneath the lower jaw, most commonly referring to the submandibular glands—small salivary glands that sit on each side under the jawbone. Investors may see the term in medical, drug or device news because conditions or treatments affecting this area (infections, tumors, surgical procedures, diagnostics) can drive clinical trial results, regulatory filings, or demand for related products, similar to how a malfunctioning part in a machine influences the need for repairs or replacements.

lax tissue medical

"It is also FDA-cleared to affect the appearance of lax tissue with submental"

Lax tissue is body tissue that has lost normal tightness or strength, so it is loose or floppy—think of an overstretched rubber band that no longer snaps back. For investors, reports mentioning lax tissue indicate a medical need that can drive demand for drugs, implants, or surgical procedures, and can affect product performance, complication rates, regulatory approvals and long‑term treatment costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• First-Time Users Can Claim $400 Off Their First Body Contouring Treatment.^*†

IRVINE, Calif., March 31, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its fourth annual CoolMonth, featuring exclusive offers on CoolSculpting^®, the treatment doctors use most for nonsurgical fat reduction.¹

Spring is often thought of as a transformative season, making the return of CoolMonth this April a perfect opportunity to reprioritize aesthetic goals. In fact, 50% of people reportedly have considered body contouring treatments (invasive and noninvasive) in preparation for summer.^2‡

CoolSculpting^® can permanently eliminate treated fat without surgery and with little to no downtime.^3,4 It is an FDA-cleared product proven to contour the body by freezing away stubborn fat.⁵

"By establishing this meaningful annual moment, we're not only translating interest into action—we're building trust and advancing education," said Glen Curran, Senior Vice President Allergan Aesthetics. "Whether patients are experiencing body changes following weight loss with GLP-1 medication, noticing specific areas resistant to diet and exercise, or simply seeking a more sculpted appearance, CoolMonth helps them take the next step toward achieving their goals."

Follow these steps to access CoolMonth offers:

• Join Allē, the Allergan Aesthetics Loyalty Program: If you're not already a member, visit Allē to register for free and take advantage of offers year-round.

• Redeem the CoolMonth First-Time Patients Promotion: New patients can claim $400 off their first CoolSculpting^® treatment starting April 1 through April 30, 2026 (while supplies last)*^†. See if you are eligible for the limited-time CoolMonth offer at https://coolscul.pt/new-patients.

• Enter for a Chance to Win Exciting Giveaways: Follow @CoolSculpting on Instagram and be on the lookout for the chance to win exciting giveaways, including up to $5,000 worth of CoolSculpting^®*.

"The spring is a great time to begin a personalized CoolSculpting^® treatment plan so you can start seeing results in time for warmer weather," said Melissa Mickelson, Co-Founder Bodify and Master Certified CoolSculpting^® Expert. Jessica Stellwagen, Co-Founder Bodify and Master Certified CoolSculpting^® Expert, continued saying, "During each consultation, we evaluate whether a patient is a good candidate, discuss their body contouring goals, and create a customized approach to help achieve their desired look. If you've been considering body contouring, CoolMonth is the perfect time to take advantage of this special offer and book your consultation."

CoolSculpting^® and CoolSculpting^® Elite are FDA-cleared for the treatment of visible fat bulges in the submental (under the chin) and submandibular (under the jawline) areas, thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments. CoolSculpting^® and CoolSculpting^® Elite are not treatments for weight loss.

To learn more about CoolSculpting^® and CoolSculpting^® Elite, the CoolMonth offerings and to find a provider near you, please visit www.CoolSculpting.com.

^*NO PURCHASE NECESSARY. Open to Allē Members in 50 U.S./D.C.; 18+ (19+ in AL, NE; 21+ in MS). You must register online at https://alle.com/sweeps/coolmonth between 12:00:01 AM PT on 4/1/26 and 11:59:59 PM PT on 4/30/26. See full Official Rules for all details and how to enter without purchase at https://alle.com/lp/coolmonth-official-rules.

^†Offers are for a limited time only and while supplies last. Terms and Conditions apply. Limited Member eligibility applies.

^‡Online survey conducted in 2023 of consumers aged between 25 to 55 with a household income of > $75,000 (N= 200 consumers aware of and interested in receiving body contouring within the next year)

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

CoolSculpting^® and CoolSculpting^® Elite Uses and Important Safety Information

Uses

CoolSculpting^® and CoolSculpting^® Elite are FDA-cleared for the treatment of visible fat bulges in the submental (under the chin) and submandibular (under the jawline) areas, thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments. CoolSculpting^® and CoolSculpting^® Elite are not treatments for weight loss.

Important Safety Information

This procedure is not for everyone. You should not be treated with CoolSculpting^® or CoolSculpting^® Elite if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.

Tell your doctor if you are pregnant or have any medical conditions including recent surgery, pre-existing hernia, and any known sensitivities or allergies.

During the procedure you may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, cramping and discomfort at the treatment site. These sensations lessen as the area becomes numb. Following the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, stinging, tenderness, cramping, skin inflammation and aching. Sensory alteration (itching, skin sensitivity, tingling, and numbness) can persist up to several weeks after treatment. You may also experience throat discomfort/soreness and sensation of fullness in the back of the throat after submental or submandibular area treatment.

Rare side effects may happen in 1 to 10 out of 10,000 CoolSculpting^® and CoolSculpting^® Elite treatments (between 0.01% to 0.1%). One such rare side effect is a visible enlargement in the treated area, which may develop 2 to 5 months after treatment, will not resolve on its own, and may require surgical intervention for correction.

Please see full Important Safety Information for CoolSculpting^® and CoolSculpting^® Elite on CoolSculpting.com.

REFERENCES:

1. Data on file, Allergan, 2025; Portfolio Aesthetic Monthly Tracker; August 2025 Data Month.
2. Data on file, Allergan, March 2023; Sizing Allergan^® Attitude & Agreement on Body Contouring Journey (NIBC) Study.
3. Stevens WG, Eagan MM, Felber C, Sarhaddi D, Orlando MV. Cryolipolysis. In: Few JW Jr, ed. The Art of Combining Surgical and Nonsurgical Techniques in Aesthetic Medicine. Thieme; 2018:132-149.
4. Avram MM, Harry RS. Cryolipolysis™ for subcutaneous fat layer reduction. Lasers in Surgery and Medicine 2009 Dec;41(10):703-8.
5. Zeltiq Aesthetics. User Manual CoolSculpting^® Elite System CS-UM- CM3-02-EN-K. 2024.

Investors:
Liz Shea
Liz.Shea@AbbVie.com
(847) 935-2211

Media:
Ember Garrett
Ember.Garrett@allergan.com
(714) 246-3525

View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-announces-fourth-annual-all-access-coolmonth-with-deals-on-coolsculpting-302729041.html

SOURCE AbbVie

FAQ

What is Allergan Aesthetics' CoolMonth promotion for ABBV in April 2026?

CoolMonth is a limited-time promotion offering $400 off first CoolSculpting treatments to eligible new Allē members. According to the company, offers run from April 1–30, 2026, are while supplies last, and specific eligibility and terms apply.

How can new patients claim the $400 CoolSculpting ABBV offer in April 2026?

New patients must join Allē and redeem the CoolMonth First-Time Patients promotion online. According to the company, registration and redemption occur between April 1 and April 30, 2026, subject to member eligibility and supply limits.

What areas are FDA-cleared for CoolSculpting and CoolSculpting Elite (ABBV)?

CoolSculpting and CoolSculpting Elite are FDA-cleared for visible fat bulges in areas such as the chin, thighs, abdomen, flanks, back, bra fat, banana roll, and upper arms. According to the company, submental treatments may also affect lax tissue appearance.

Are CoolSculpting treatments part of weight-loss programs according to ABBV's announcement?

No, CoolSculpting and CoolSculpting Elite are not treatments for weight loss. According to the company, these procedures are intended to permanently reduce treated fat bulges without surgery, with little to no downtime.

How can ABBV customers enter giveaways and what prizes are available during CoolMonth 2026?

Customers can follow @CoolSculpting on Instagram and participate in promotions for a chance to win giveaways. According to the company, prizes include giveaways up to $5,000 of CoolSculpting services, with official rules and entry windows applying.